Is Caplin Point Laboratories a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Caplin Point Laboratories Ltd is a average quality company .

Is Caplin Point Laboratories undervalued or overvalued?

The key valuation ratios of Caplin Point Laboratories Ltd's currently when compared to its past seem to suggest it is in the Fair zone .

What is Caplin Point Laboratories share price return in the past 10 years?

Caplin Point Laboratories Ltd share price has appreciated 40% annually (CAGR) over the past ten years.

Is Caplin Point Laboratories a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Caplin Point Laboratories Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

What is the P/E ratio of Caplin Point Laboratories?

The latest standalone P/E ratio of Caplin Point Laboratories as of 20-Dec-2024 is 57.86.

What is the P/B ratio of Caplin Point Laboratories?

The latest standalone P/B ratio of Caplin Point Laboratories as of 20-Dec-2024 is 11.44.

What is the 52-week high and low of Caplin Point Laboratories?

The 52-week high of Caplin Point Laboratories is Rs. 2540.00 and the 52-week low is Rs. 1221.00.

Caplin Point Laboratories Ltd - Stock Valuation and Financial Performance

Name: Caplin Point Laboratories
Brand: Caplin Point Laboratories

BSE: 524742 | NSE: CAPLIPOINT | Pharmaceuticals & Drugs | Small Cap

Place order

Caplin Point Lab Share Price

₹2,311.05 -80.70 -3.37%
as on 20-Dec'24 16:59

10 Year X-Ray of Caplin Point Lab:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Jun'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
ROCE % ⓘ	71.1%	55.4%	69%	64.1%	45.6%	33.4%	28.8%	28.8%	26.9%	26.9%	-
Value Creation Index ⓘ	4.1	3.0	3.9	3.6	2.3	1.4	1.1	1.1	1.0	1.0	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	252	318	402	540	649	863	1,061	1,269	1,467	1,694	1,831
Sales YoY Gr.	-	26.4%	26.2%	34.4%	20.2%	33.1%	23%	19.6%	15.5%	15.5%	-
Adj EPS ⓘ	5.7	8.4	12.4	18.6	22.3	25.9	32.4	38.6	48.5	59.2	64.9
YoY Gr.	-	48.5%	46.9%	50.2%	20%	16.1%	25.2%	18.9%	25.7%	22.1%	-
BVPS (₹) ⓘ	11.8	21.7	29.7	47.7	78	114.2	144.9	183.9	235.9	293.2	334.5
Adj Net Profit ⓘ	42.9	63.6	93.5	141	169	196	245	292	367	449	493
Cash Flow from Ops. ⓘ	49.9	56.5	67.6	66.5	83.4	44.7	269	337	271	318	-
Debt/CF from Ops. ⓘ	0	0.1	0	0	0	0.8	0.1	0	0	0	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	23.6%	21.2%	16.9%	15.5%
Adj EPS ⓘ	29.8%	21.6%	22.2%	22.1%
BVPSⓘ	42.9%	30.3%	26.5%	24.3%
Share Price	40%	49.2%	44.9%	64.5%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Jun'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
Return on Equity % ⓘ	55.3	43.1	53	47.7	33.8	24.8	23	21.9	21.8	21.4	20.7
Op. Profit Mgn % ⓘ	24.8	28.1	31.2	36.2	35.7	30.1	31	31.1	30.1	32.6	33
Net Profit Mgn % ⓘ	17.1	20	23.3	26	26	22.7	24	23.7	25.1	26.8	27
Debt to Equity ⓘ	0	0	0	0	0	0	0	0	0	0	0
Working Cap Days ⓘ	47	71	67	95	133	176	197	211	221	225	187
Cash Conv. Cycle ⓘ	-49	-68	-51	-19	33	112	115	94	98	115	155

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 16.87%

Net Profit is growing at healthy rate in last 3 years 22.20%

Sales growth is good in last 4 quarters at 16.85%

Return on Equity has declined versus last 3 years average to 20.70%

Latest Financials - Caplin Point Laboratories Ltd.

	Standalone	Consolidated
TTM EPS (₹)	39.9	64.9
TTM Sales (₹ Cr.)	666	1,831
BVPS (₹.) ⓘ	201.9	334.5
Reserves (₹ Cr.) ⓘ	1,539	2,527
P/BV ⓘ	11.44	6.91
PE ⓘ	57.86	35.59

From the Market
52 Week Low / High (₹)	1221.00 / 2540.00
All Time Low / High (₹)	0.18 / 2540.00
Market Cap (₹ Cr.)	17,567
Equity (₹ Cr.)	15.2
Face Value (₹)	2
Industry PE ⓘ	44.3

Management X-Ray of Caplin Point Lab:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Caplin Point Lab

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Caplin Point Lab

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Jun'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Sales	252	239	402	540	649	863	1,061	1,269	1,467	1,694
Operating Expenses ⓘ	192	175	277	345	417	603	737	875	1,026	1,143
Manufacturing Costs	25	22	38	48	57	83	86	103	117	151
Material Costs	136	121	185	238	289	413	472	558	663	724
Employee Cost	18	18	30	38	46	67	102	115	136	143
Other Costs ⓘ	14	14	24	21	25	40	77	99	110	125
Operating Profit ⓘ	60	64	125	195	232	260	324	395	441	551
Operating Profit Margin (%)	23.7%	26.9%	31.1%	36.2%	35.7%	30.1%	30.6%	31.1%	30.0%	32.6%
Other Income ⓘ	3	4	10	13	19	41	28	39	57	67
Interest ⓘ	1	0	1	1	1	0	2	1	1	1
Depreciation ⓘ	8	7	13	19	23	32	37	47	45	53
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Profit Before Tax ⓘ	53	60	121	188	227	269	314	386	451	564
Tax ⓘ	12	14	25	44	50	54	62	77	74	103
Profit After Tax	41	46	96	145	177	215	251	308	377	461
PAT Margin (%)	16.3%	19.2%	23.8%	26.8%	27.2%	24.9%	23.7%	24.3%	25.7%	27.2%
Adjusted EPS (₹)	5.4	6.1	12.7	19.2	23.3	28.4	32.0	39.6	49.6	60.2
Dividend Payout Ratio (%)	18%	20%	12%	10%	9%	9%	9%	10%	9%	8%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Jun'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Equity and Liabilities
Shareholders Fund	93	127	225	361	626	938	1,171	1,468	1,865	2,301
Share Capital ⓘ	15	15	15	15	51	90	90	90	90	90
Reserves ⓘ	78	111	210	345	575	849	1,081	1,379	1,775	2,212
Minority Interest	0	0	0	0	0	9	18	26	27	31
Debt	1	1	0	0	0	0	0	1	3	0
Long Term Debt	1	1	0	0	0	0	0	0	0	0
Short Term Debt	0	0	0	0	0	0	0	1	3	0
Trade Payables	42	56	79	94	60	64	89	156	153	209
Others Liabilities ⓘ	93	84	54	45	56	114	87	79	130	143
Total Liabilities ⓘ	229	267	358	500	743	1,126	1,364	1,730	2,177	2,686
Fixed Assets
Gross Block	143	181	195	232	272	355	423	446	480	702
Accumulated Depreciation	30	37	43	62	45	82	117	159	201	250
Net Fixed Assetsⓘ	113	144	152	169	227	273	305	287	280	453
CWIP ⓘ	31	0	3	15	10	20	14	18	221	117
Investmentsⓘ	0	0	17	47	70	61	11	89	281	376
Inventories	14	19	22	28	37	238	179	227	288	363
Trade Receivables	6	8	33	126	160	229	279	317	394	543
Cash Equivalents	45	68	93	79	153	223	438	463	493	553
Others Assetsⓘ	20	27	37	35	86	82	136	329	220	282
Total Assets ⓘ	229	267	358	500	743	1,126	1,364	1,730	2,177	2,686

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Jun'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Cash Flow From Operating Activity ⓘ	50	42	68	66	83	45	269	337	271	318
PBT ⓘ	53	60	121	188	227	269	314	386	451	564
Adjustment ⓘ	6	4	9	15	19	7	23	30	12	2
Changes in Working Capital ⓘ	2	-5	-38	-100	-120	-177	-2	2	-104	-139
Tax Paid ⓘ	-12	-16	-24	-36	-43	-55	-66	-81	-88	-109
Cash Flow From Investing Activity ⓘ	-23	-6	-36	-69	-100	-55	-29	-377	-218	-320
Capex	-25	-8	-25	-49	-65	-77	-73	-91	-193	-146
Net Investments	0	0	-17	-27	-20	10	24	-200	-49	-93
Others ⓘ	3	2	6	7	-15	13	20	-85	25	-81
Cash Flow From Financing Activityⓘ	-9	-14	-7	-12	90	80	-24	-41	-28	-38
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	-1	0	0	0	0	0	-19	-17	0	0
Interest Paid ⓘ	0	0	0	0	0	0	-2	-1	-1	-1
Dividend Paid ⓘ	-7	-14	-6	-11	-15	-33	-3	-23	-30	-34
Others ⓘ	0	0	0	0	105	113	0	-1	3	-3
Net Cash Flow ⓘ	19	23	25	-14	73	70	215	-81	26	-40

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Jun'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Ratios
ROE (%)	55.78	43.13	54.97	49.43	37.14	29.58	25.65	24.77	23.68	22.97
ROCE (%)	71.11	55.41	69.03	64.08	45.59	33.35	28.82	28.77	26.85	26.92
Asset Turnover Ratio	1.23	0.96	1.28	1.26	1.04	0.92	0.85	0.82	0.75	0.7
PAT to CFO Conversion(x)	1.22	0.91	0.71	0.46	0.47	0.21	1.07	1.09	0.72	0.69
Working Capital Days
Receivable Days	4	10	19	54	80	82	87	86	88	101
Inventory Days	17	25	19	17	19	58	72	58	64	70
Payable Days	98	147	133	132	98	55	59	80	85	91

Caplin Point Laboratories Ltd Stock News

Caplin Point Laboratories Ltd FAQs

What is the share price of Caplin Point Lab?

Company share prices are keep on changing according to the market conditions. The closing price of Caplin Point Lab on 20-Dec-2024 16:59 is ₹2,311.1.

What is the market cap of Caplin Point Lab?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 20-Dec-2024 16:59 the market cap of Caplin Point Lab stood at ₹17,566.7.

What is the P/E ratio of Caplin Point Lab?

The latest P/E ratio of Caplin Point Lab as of 20-Dec-2024 16:59 is 57.86.

What is the P/B ratio of Caplin Point Lab?

The latest P/B ratio of Caplin Point Lab as of 20-Dec-2024 16:59 is 11.44.

What is the 52-week high and low of Caplin Point Lab?

The 52-week high of Caplin Point Lab is ₹2,540 and the 52-week low is ₹1,221.

What is the TTM revenue of Caplin Point Lab?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Caplin Point Lab is ₹665.8 ( Cr.) .

About Caplin Point Laboratories Ltd

Caplin Point Laboratories was established in 1990 to manufacture a range of ointments, creams and other external applications. The Company was listed in 1994; the IPO proceeds were deployed in a manufacturing facility in Pondicherry. The promoters exposed their lives to physical risk when they ventured into war-affected countries more than two decades ago. The Company ventured into the emerging markets of West Africa, Latin America and The Caribbean to market finished formulations. The Company’s asset-light marketing business model has helped generate the resources to build world-class infrastructure.

The success of Caplin Point is primarily attributed to its unique business model. Starting of as an SME, Caplin Point decided at an early stage that the conventional style of exports would mean diminishing margins and reduced opportunities for expansion, and had taken the unique step of creating last mile logistical solutions for its exclusive distributors across Latin America and various parts of Africa. This way, Caplin Point is able to generate adequate revenue and cash flow to remain debt-free with benchmark receivables, and also continue to invest in state of the art manufacturing facilities from internal accruals. One of the main reasons for the success can be attributed to the wide range of products offered across diverse geographies.

Business area of the company

Caplin Point is the mid-sized company in India’s pharmaceutical sector to be engaged in the manufacture of APIs, finished formulations, research & development, clinical research, frontend generic presence in Latin America, brand marketing in Francophone Africa and an USFDA approved injectable facility.

Products

Liquid Injections
Lyophilised Injections
Opthalmic
Tablets
Liquid Orals
Capsule
Softgel Capsules
Suppositories & Ovules
Powder for Injection
Dry syrup
Topicals
Liquid Injections
Inhalers
Ophthalmic
IV Infusion
Lyophilised Products
Branded Products
Dermo Cosmetics

Awards and recognitions

2014: Forbes Asia Best under a Billion Award - 2014.
2015: Forbes Asia Best under a Billion Award - 2015.
2016: Forbes Asia Best under a Billion Award - 2016.
2017: Nanayam Vikatan’s Gold Phoenix Award to Mr. C C Paarthipan.
2017: Financial express CFO Awards 2017 (Second Rank).
2017: IPF’s industrial Excellance Award.
2018: The Economic Times - Family Business of the year Award.
2018: Pharmexcil Outstanding Exports Award 2018.
2018: The Economic Times Award for Excellence in Business Performance.
2019: Empowering India Awards 2019 in Pharmaceutical, Healthcare and Bio-Technology Segment.